Data / Research funding / Texas / University of TX MD Anderson Can CTR
University of TX MD Anderson Can CTR: 684 NIH awards ($956.9M) and 1 NSF award ($242.5K), fiscal years 2021 to 2026
University of TX MD Anderson Can CTR in Houston, TX is funded under 684 NIH awards ($956.9M) and 1 NSF award ($242.5K) in the NIH and NSF award files, read 2026-11-04. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- S3GMKS8ELA16
- State
- Texas
Awards
The 500 largest of 685 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $59,316,664 | August 28, 1996 | June 30, 2026 | DRAETTA, GIULIO FRANCESCO | reporter.nih.gov |
| Genetics and Biology of Pancreatic Ductal Adenocarcinoma | NIH | National Cancer Institute | 2021 to 2025 | $11,776,572 | December 1, 2005 | March 31, 2026 | DEPINHO, RONALD ANTHONY | reporter.nih.gov |
| SPORE in Brain Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,413,880 | September 1, 2008 | August 31, 2029 | LANG, FREDERICK F | reporter.nih.gov |
| Mechanisms controlling distinct growth and functional characteristics of the perinatal and adult thymus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,704,616 | September 1, 2020 | August 31, 2025 | RICHIE, ELLEN R | reporter.nih.gov |
| Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $9,632,234 | September 28, 2015 | June 30, 2030 | LI, LIANG | reporter.nih.gov |
| Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $9,423,468 | September 15, 2023 | March 14, 2027 | WU, XIANGWEI | reporter.nih.gov |
| Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR) | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $7,246,135 | August 15, 2017 | April 30, 2028 | HOPKINS, WILLIAM D | reporter.nih.gov |
| UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1 | NIH | National Cancer Institute | 2021 to 2025 | $7,237,503 | March 5, 2019 | February 28, 2026 | TSAO, ANNE S | reporter.nih.gov |
| iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,046,172 | August 15, 2019 | July 31, 2031 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $6,893,291 | September 19, 2023 | August 2, 2025 | SOOD, ANIL K | reporter.nih.gov |
| The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $6,641,253 | September 25, 2019 | August 31, 2025 | BERETTA, LAURA | reporter.nih.gov |
| MD Anderson Cancer Center SPORE in Gastrointestinal Cancer | NIH | National Cancer Institute | 2021 to 2023 | $6,402,532 | August 20, 2019 | May 31, 2025 | KOPETZ, SCOTT | reporter.nih.gov |
| The University of Texas MD Anderson Cancer Center SPORE in Melanoma | NIH | National Cancer Institute | 2021 to 2023 | $6,072,928 | July 16, 2019 | May 31, 2025 | DAVIES, MICHAEL | reporter.nih.gov |
| Squirrel Monkey Breeding and Research Resource | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $5,901,087 | April 1, 1997 | July 31, 2025 | HOPKINS, WILLIAM D | reporter.nih.gov |
| Center for Transformative Community-Driven Research to Prevent Obesity-related Cancer | NIH | National Cancer Institute | 2023 to 2025 | $5,869,013 | June 15, 2023 | April 30, 2028 | BASEN-ENGQUIST, KAREN M | reporter.nih.gov |
| Acquired Resistance to Therapy and Iron (ARTI) Center | NIH | National Cancer Institute | 2022 to 2025 | $5,719,340 | September 20, 2022 | August 31, 2027 | GAN, BOYI | reporter.nih.gov |
| MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC | NIH | National Cancer Institute | 2023 to 2025 | $5,677,452 | September 30, 2017 | June 30, 2028 | HAYMAKER, CARA L | reporter.nih.gov |
| The Houston Center for Acquired Resistance Research (H-CARR) | NIH | National Cancer Institute | 2022 to 2025 | $5,352,094 | September 20, 2022 | August 31, 2027 | MYERS, JEFFREY NICHOLAS | reporter.nih.gov |
| Texas EXperimental Cancer Therapeutics Network - TEX CTN | NIH | National Cancer Institute | 2023 to 2025 | $5,310,583 | March 14, 2014 | February 28, 2027 | MERIC-BERNSTAM, FUNDA | reporter.nih.gov |
| Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D) | NIH | National Cancer Institute | 2024 to 2025 | $5,158,661 | September 1, 2024 | August 31, 2029 | WANG, LINGHUA | reporter.nih.gov |
| Novel Cord Blood-Derived Cellular Therapies | NIH | National Cancer Institute | 2021 to 2022 | $5,119,777 | September 22, 2011 | August 31, 2025 | SHPALL, ELIZABETH J | reporter.nih.gov |
| Clinical Validation Center for Lung Cancer Early Detection | NIH | National Cancer Institute | 2022 to 2025 | $4,880,009 | September 1, 2022 | August 31, 2027 | HANASH, SAMIR M | reporter.nih.gov |
| Great Lakes New England Clinical Validation Center | NIH | National Cancer Institute | 2022 to 2025 | $4,820,800 | May 15, 2000 | August 31, 2027 | RICCIARDIELLO, LUIGI | reporter.nih.gov |
| OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVIVORship | NIH | National Cancer Institute | 2024 to 2025 | $4,789,290 | September 1, 2024 | August 31, 2029 | HUTCHESON, KATHERINE ARNOLD | reporter.nih.gov |
| Effects of Tissue Block Age on Reliability and Accuracy of In situ Transcriptomics Across Organ Sites using Xenium Technology | NIH | National Cancer Institute | 2022 to 2024 | $4,748,687 | September 21, 2022 | August 31, 2027 | MAITRA, ANIRBAN | reporter.nih.gov |
| Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,382,400 | March 5, 2019 | February 28, 2026 | EVANS, SCOTT E. | reporter.nih.gov |
| SPORE University of Texas M. D. Anderson Cancer Center-Leukemia | NIH | National Cancer Institute | 2021 to 2023 | $4,298,278 | September 1, 2023 | August 31, 2024 | SHPALL, ELIZABETH J | reporter.nih.gov |
| Mesoscale and Nanoscale Technologies Integrated by Structures for DNA Repair Complexes (MANTIS-DRC) | NIH | National Cancer Institute | 2021 to 2025 | $4,277,979 | September 13, 2018 | August 31, 2032 | TAINER, JOHN A. | reporter.nih.gov |
| Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patients | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,805,993 | June 1, 2021 | May 31, 2027 | LIAO, ZHONGXING | reporter.nih.gov |
| Alzheimer's Disease Pathology in a Primate Model | NIH | National Institute on Aging | 2021 to 2025 | $3,764,077 | February 15, 2021 | January 31, 2027 | HOPKINS, WILLIAM D | reporter.nih.gov |
| Processing and Repair of DNA Crosslinks | NIH | National Cancer Institute | 2021 to 2022 | $3,648,083 | February 10, 2017 | January 31, 2023 | WOOD, RICHARD D | reporter.nih.gov |
| Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,563,506 | August 7, 2018 | July 31, 2029 | SEN, SUBRATA | reporter.nih.gov |
| MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm | NIH | National Cancer Institute | 2021 to 2025 | $3,471,925 | May 5, 2016 | May 31, 2028 | BAST, ROBERT C | reporter.nih.gov |
| Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevance | NIH | National Cancer Institute | 2022 to 2025 | $3,463,660 | September 1, 2022 | August 31, 2027 | SCHUELER, EMIL | reporter.nih.gov |
| Exploring DNA damage response pathways as targets for cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $3,431,390 | September 1, 2022 | August 31, 2029 | CHEN, JUNJIE | reporter.nih.gov |
| Testing the impact of a multi-level intervention on cancer prevention behavior among young adults in Texas | NIH | National Cancer Institute | 2021 to 2025 | $3,426,696 | August 1, 2021 | July 31, 2027 | LU, QIAN | reporter.nih.gov |
| Peer-Based Approaches to Enhance Physical Activity in Dyads of Inactive Women | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,417,908 | May 1, 2021 | April 30, 2027 | STRONG, LARKIN | reporter.nih.gov |
| Biology and Function of Exosomes in Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,385,880 | September 1, 2022 | August 31, 2029 | KALLURI, RAGHU | reporter.nih.gov |
| Cancer Immune-Interception for Lynch Syndrome | NIH | National Cancer Institute | 2021 to 2025 | $3,326,163 | September 21, 2021 | August 31, 2026 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2) | NIH | National Cancer Institute | 2021 to 2023 | $3,314,224 | August 16, 2002 | August 31, 2025 | GIORDANO, SHARON HERMES | reporter.nih.gov |
| Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,278,152 | September 1, 2022 | August 31, 2028 | LAI, STEPHEN Y | reporter.nih.gov |
| Statistical Modeling of Alzheimer's Disease Progression Integrating Brain Imaging and -Omics Data | NIH | National Institute on Aging | 2021 to 2025 | $3,255,277 | July 27, 2021 | February 28, 2027 | KUNDU, SUPRATEEK | reporter.nih.gov |
| Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,249,330 | January 1, 2020 | March 31, 2030 | CHENG, XIAODONG | reporter.nih.gov |
| Clinical Validation Center for Early Detection of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,231,816 | May 4, 2016 | August 31, 2027 | MAITRA, ANIRBAN | reporter.nih.gov |
| Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,218,917 | August 15, 2015 | June 30, 2026 | JENQ, ROBERT | reporter.nih.gov |
| Imaging-based tumor forecasting to predict brain tumor progression and response to therapy | NIH | National Cancer Institute | 2022 to 2025 | $3,208,620 | September 19, 2022 | August 31, 2028 | QUARLES, CHRISTOPHER CHAD | reporter.nih.gov |
| Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,159,973 | September 16, 2021 | August 31, 2026 | WU, JIA | reporter.nih.gov |
| The AVANÇO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV | NIH | National Cancer Institute | 2023 to 2025 | $3,150,121 | August 1, 2023 | July 31, 2028 | SCHMELER, KATHLEEN | reporter.nih.gov |
| The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic Data | NIH | National Cancer Institute | 2022 to 2025 | $3,120,147 | July 1, 2022 | June 30, 2027 | LIANG, HAN | reporter.nih.gov |
| Training of Academic Surgical Oncologists | NIH | National Cancer Institute | 2021 to 2025 | $3,086,804 | May 25, 1994 | February 29, 2028 | WARGO, JENNIFER A. | reporter.nih.gov |
| Patient-Derived Models of Prostate Cancer for Personalized Medicine | NIH | National Cancer Institute | 2021 to 2023 | $3,037,013 | August 1, 2019 | July 31, 2025 | FUTREAL, PHILLIP ANDREW | reporter.nih.gov |
| Writing to Heal: A Culturally Based Brief Expressive Writing Intervention for Chinese Immigrant Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2025 | $2,983,485 | July 1, 2021 | June 30, 2027 | LU, QIAN | reporter.nih.gov |
| A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,980,235 | April 1, 2021 | March 31, 2027 | KASEB, AHMED | reporter.nih.gov |
| Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment Resistance | NIH | National Cancer Institute | 2021 to 2025 | $2,957,676 | June 1, 2025 | May 31, 2027 | AMIT, MORAN | reporter.nih.gov |
| Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response | NIH | National Cancer Institute | 2021 to 2025 | $2,957,123 | June 1, 2021 | May 31, 2026 | BYERS, LAUREN AVERETT | reporter.nih.gov |
| Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,945,301 | August 1, 2021 | June 30, 2027 | LI, SHULIN | reporter.nih.gov |
| Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,937,308 | April 1, 2021 | March 31, 2026 | GENOVESE, GIANNICOLA | reporter.nih.gov |
| Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,933,453 | July 15, 2022 | April 30, 2027 | HOWELL, REBECCA MAUREEN | reporter.nih.gov |
| DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition | NIH | National Cancer Institute | 2022 to 2025 | $2,923,293 | September 21, 2022 | August 31, 2027 | BAST, ROBERT C | reporter.nih.gov |
| PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education) | NIH | National Cancer Institute | 2022 to 2024 | $2,916,000 | September 16, 2022 | August 31, 2027 | MAITRA, ANIRBAN | reporter.nih.gov |
| Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $2,900,314 | August 13, 2019 | May 31, 2025 | FULLER, CLIFTON DAVID | reporter.nih.gov |
| Identifying and targeting collateral lethal vulnerabilities in cancers | NIH | National Cancer Institute | 2023 to 2025 | $2,852,762 | April 1, 2023 | March 31, 2028 | DEPINHO, RONALD ANTHONY | reporter.nih.gov |
| Harnessing the nervous system to overcome resistance to immunotherapy in oral cancer | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,825,170 | August 1, 2022 | May 31, 2027 | AMIT, MORAN | reporter.nih.gov |
| Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,807,941 | July 1, 2025 | June 30, 2027 | LISSANU, YONATHAN | reporter.nih.gov |
| Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions | NIH | National Cancer Institute | 2022 to 2025 | $2,781,461 | September 16, 2022 | August 31, 2027 | YUAN, YING | reporter.nih.gov |
| Paul Calabresi Clinical Oncology Award | NIH | National Cancer Institute | 2022 to 2025 | $2,729,519 | September 13, 2000 | June 30, 2027 | KOPETZ, SCOTT | reporter.nih.gov |
| Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome | NIH | National Cancer Institute | 2022 to 2025 | $2,721,586 | August 22, 2022 | July 31, 2027 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,717,589 | September 19, 2023 | August 31, 2025 | YEE, CASSIAN | reporter.nih.gov |
| [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events | NIH | National Cancer Institute | 2022 to 2025 | $2,714,023 | September 1, 2022 | August 31, 2027 | PIWNICA-WORMS, DAVID | reporter.nih.gov |
| BAF complex deregulation in lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,711,912 | August 2, 2022 | July 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2 | NIH | National Cancer Institute | 2021 to 2025 | $2,686,065 | April 1, 2021 | September 30, 2026 | KURIE, JONATHAN M | reporter.nih.gov |
| Training of Academic Gynecologic Oncologists | NIH | National Cancer Institute | 2021 to 2025 | $2,684,417 | September 15, 2005 | June 30, 2026 | SOOD, ANIL K | reporter.nih.gov |
| Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi) | NIH | National Cancer Institute | 2022 to 2025 | $2,651,373 | January 1, 2022 | December 31, 2026 | REYES-GIBBY, CIELITO C | reporter.nih.gov |
| Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $2,641,385 | August 1, 2021 | July 31, 2027 | GAO, JIANJUN | reporter.nih.gov |
| The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,641,121 | September 1, 2020 | May 31, 2027 | ROBINSON, JASON D | reporter.nih.gov |
| Impact of aging on metastatic competence of the omentum | NIH | National Cancer Institute | 2025 | $2,638,738 | August 1, 2025 | July 31, 2029 | NAORA, HONAMI | reporter.nih.gov |
| Early Detection of Hepatocellular Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,637,669 | June 3, 2016 | February 28, 2027 | BERETTA, LAURA | reporter.nih.gov |
| Role of GRAIL in B cell tolerance and B-cell mediated inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,630,572 | August 1, 2025 | July 31, 2029 | NURIEVA, ROZA INSAFETDINOVNA | reporter.nih.gov |
| Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy | NIH | National Cancer Institute | 2022 to 2025 | $2,603,837 | August 1, 2022 | June 30, 2027 | LI, CHUN | reporter.nih.gov |
| Anatomic, Physiologic and Transcriptomic Mechanisms of Neuropathic Pain in Human DRG | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,590,497 | April 15, 2020 | February 28, 2026 | DOUGHERTY, PATRICK M | reporter.nih.gov |
| Lymphoma Outcomes SPORE | NIH | National Cancer Institute | 2025 | $2,561,113 | August 22, 2025 | July 31, 2030 | FLOWERS, CHRISTOPHER R | reporter.nih.gov |
| Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,543,302 | February 19, 2021 | January 31, 2027 | KADARA, HUMAM | reporter.nih.gov |
| Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance | NIH | National Cancer Institute | 2022 to 2025 | $2,524,055 | July 15, 2022 | June 30, 2027 | WANG, LINGHUA | reporter.nih.gov |
| Enhanced Biomechanical Modeling of the Breast for Womens Health | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,473,996 | June 10, 2022 | February 28, 2027 | BROCK, KRISTY | reporter.nih.gov |
| InHANCE: Imaging Innovation for Head And Neck Cancer Evaluation & Treatment Delivery | NIH | National Cancer Institute | 2025 | $2,457,127 | August 18, 2025 | July 31, 2030 | BROCK, KRISTY | reporter.nih.gov |
| Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 | NIH | National Cancer Institute | 2021 to 2025 | $2,439,831 | December 1, 2020 | November 30, 2025 | BHALLA, KAPIL | reporter.nih.gov |
| Developing novel bispecific antibodies for cancer treatment | NIH | National Cancer Institute | 2021 to 2025 | $2,437,200 | July 1, 2021 | June 30, 2027 | FAN, ZHEN | reporter.nih.gov |
| Molecular Photoacoustic Imaging for Diagnostics and Therapy Monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,418,638 | August 1, 2020 | April 30, 2025 | BOUCHARD, RICHARD R. | reporter.nih.gov |
| Development of Pathology-activated Drugs for Treatment of Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $2,408,109 | September 20, 2022 | August 31, 2024 | GRACE, PETER M | reporter.nih.gov |
| Research Training in Academic Medical Oncology | NIH | National Cancer Institute | 2021 to 2024 | $2,407,586 | September 30, 1994 | April 30, 2026 | DAVIES, MICHAEL | reporter.nih.gov |
| Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor | NIH | National Cancer Institute | 2022 to 2025 | $2,406,344 | August 3, 2022 | July 31, 2027 | TWEARDY, DAVID JOHN | reporter.nih.gov |
| A pro-metastatic secretory pathway activated by p53 loss in lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,399,783 | July 1, 2021 | December 31, 2026 | KURIE, JONATHAN M | reporter.nih.gov |
| Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,389,102 | September 1, 2022 | July 31, 2027 | KADARA, HUMAM | reporter.nih.gov |
| In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,362,124 | August 2, 2022 | July 31, 2027 | SOKOLOV, KONSTANTIN V | reporter.nih.gov |
| Regulation of Peripheral Neuropathic Pain by B Cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,308,227 | March 15, 2022 | February 28, 2027 | GRACE, PETER M | reporter.nih.gov |
| Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,305,974 | March 1, 2022 | February 28, 2027 | FEDIRKO, VERONIKA | reporter.nih.gov |
| A technological approach for performance status assessment in advanced cancer patients | NIH | National Cancer Institute | 2021 to 2024 | $2,303,837 | February 1, 2020 | January 31, 2026 | PETERSON, SUSAN K | reporter.nih.gov |
| Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,299,787 | July 1, 2022 | June 30, 2027 | LIZEE, GREGORY A | reporter.nih.gov |
| Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma | NIH | National Cancer Institute | 2022 to 2025 | $2,296,728 | February 1, 2022 | January 31, 2027 | LI, CHUN | reporter.nih.gov |
| Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy | NIH | National Cancer Institute | 2022 to 2025 | $2,272,686 | June 15, 2022 | May 31, 2027 | TOUMAZIS, IAKOVOS | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2025 | $2,270,520 | September 19, 2023 | August 31, 2028 | YEE, CASSIAN | reporter.nih.gov |
| Determining the optimal ion and fractionation scheme for the treatment of GBM in a comprehensive human organoid model | NIH | National Cancer Institute | 2021 to 2025 | $2,268,156 | March 1, 2021 | February 28, 2026 | GROSSHANS, DAVID R | reporter.nih.gov |
| Deciphering the hierarchical modularity of the mammalian cell through network integration and complex genetic perturbation strategies | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,263,715 | August 1, 2018 | August 31, 2028 | HART, TRAVER | reporter.nih.gov |
| Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors | NIH | National Cancer Institute | 2021 to 2024 | $2,260,368 | April 1, 2020 | September 30, 2025 | HEYMACH, JOHN V. | reporter.nih.gov |
| Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,258,753 | April 1, 2021 | March 31, 2026 | VIALE, ANDREA | reporter.nih.gov |
| Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,242,875 | August 1, 2023 | July 31, 2027 | JIANG, WEN | reporter.nih.gov |
| Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,226,458 | April 1, 2021 | March 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,213,464 | May 3, 2022 | February 28, 2027 | MYERS, JEFFREY NICHOLAS | reporter.nih.gov |
| A Pathway of Tumor Suppression | NIH | National Cancer Institute | 2021 to 2025 | $2,208,913 | July 1, 1988 | April 30, 2027 | LOZANO, GUILLERMINA | reporter.nih.gov |
| Dissecting the Source and Mechanisms of IL-17-Mediated Modulation of Pancreatic Tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $2,204,373 | September 18, 2020 | August 31, 2027 | MCALLISTER, FLORENCIA | reporter.nih.gov |
| The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in Zambia | NIH | National Cancer Institute | 2023 to 2025 | $2,188,094 | September 19, 2023 | August 31, 2028 | LIN, LILIE LEMING | reporter.nih.gov |
| Therapeutic strategies against EGFR exon 20 mutant lung cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,179,752 | December 1, 2019 | November 30, 2024 | HEYMACH, JOHN V. | reporter.nih.gov |
| Premature aging disorders, metabolites, and atherosclerosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,173,716 | December 15, 2022 | November 30, 2026 | ABE, JUN-ICHI | reporter.nih.gov |
| Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,171,748 | June 15, 2021 | April 30, 2026 | JIANG, WEN | reporter.nih.gov |
| Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $2,164,975 | December 1, 2020 | November 30, 2025 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models | NIH | National Cancer Institute | 2021 to 2025 | $2,164,771 | July 10, 2015 | June 30, 2026 | GORLICK, RICHARD G. | reporter.nih.gov |
| Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients | NIH | National Cancer Institute | 2021 to 2025 | $2,161,269 | December 9, 2020 | November 30, 2026 | KEYOMARSI, KHANDAN | reporter.nih.gov |
| Characterization and modeling of m6A RNA methylation in cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,150,624 | September 1, 2020 | May 31, 2026 | LIANG, HAN | reporter.nih.gov |
| Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,146,722 | March 1, 2019 | August 31, 2025 | LIN, CHUNRU | reporter.nih.gov |
| A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical Cancer Risk Reduction in HIV+ Women living in Mozambique | NIH | National Cancer Institute | 2022 to 2025 | $2,124,467 | May 12, 2020 | July 31, 2027 | SCHMELER, KATHLEEN | reporter.nih.gov |
| Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,112,899 | July 1, 2022 | June 30, 2027 | LISSANU, YONATHAN | reporter.nih.gov |
| Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $2,109,951 | April 1, 2023 | January 31, 2028 | LAI, STEPHEN Y | reporter.nih.gov |
| Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. | NIH | National Cancer Institute | 2025 | $2,108,734 | September 1, 2025 | August 31, 2030 | CZERNIAK, BOGDAN A | reporter.nih.gov |
| Novel combination therapy for AML expressing mutant RUNX1 | NIH | National Cancer Institute | 2021 to 2024 | $2,088,671 | September 1, 2021 | August 31, 2025 | DINARDO, COURTNEY | reporter.nih.gov |
| Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies | NIH | National Cancer Institute | 2022 to 2025 | $2,067,707 | July 5, 2022 | June 30, 2027 | YU, DIHUA | reporter.nih.gov |
| The molecular and genetic bases of diverse tissue repair responses in postembryonic Drosophila | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,063,600 | April 1, 2018 | April 2, 2026 | GALKO, MICHAEL J | reporter.nih.gov |
| Radiomic and genomic predictors of breast cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $2,041,484 | September 13, 2021 | November 30, 2026 | SIEH, WEIVA | reporter.nih.gov |
| ERK-mediated regulation of non-coding RNAs during development and disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,025,000 | September 10, 2021 | September 30, 2026 | ARUR, SWATHI | reporter.nih.gov |
| Neutrophil Extracellular Traps and Host Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,025,000 | March 4, 2021 | February 28, 2027 | SHARMA, JYOTIKA | reporter.nih.gov |
| University of Texas PDX Development and Trial Center | NIH | National Cancer Institute | 2021 to 2022 | $2,017,306 | September 30, 2017 | June 30, 2023 | ROTH, JACK | reporter.nih.gov |
| Harnessing the power of exosomes for non-coding RNA delivery | NIH | National Cancer Institute | 2021 to 2023 | $2,011,604 | August 2, 2017 | July 31, 2025 | SOOD, ANIL K | reporter.nih.gov |
| A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously | NIH | National Cancer Institute | 2021 to 2024 | $2,007,018 | July 1, 2020 | June 30, 2025 | KWONG, LAWRENCE | reporter.nih.gov |
| Optimizing Detection and Interventions Against Rare Pre-existing Drug Resistance Mutations | NIH | National Human Genome Research Institute | 2021 to 2023 | $1,993,773 | September 21, 2020 | June 30, 2025 | KWONG, LAWRENCE | reporter.nih.gov |
| Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers | NIH | National Cancer Institute | 2023 to 2025 | $1,988,595 | September 11, 2023 | August 31, 2028 | MILBURY, KATHRIN | reporter.nih.gov |
| Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,983,279 | September 1, 2023 | August 31, 2028 | FAHRMANN, JOHANNES F | reporter.nih.gov |
| Mitigating radiation-induced cardiovascular disease by inhibiting premature aging | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,981,072 | July 1, 2020 | June 30, 2025 | ABE, JUN-ICHI | reporter.nih.gov |
| 3D Spatial Multi-Omics Profiling of Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,979,214 | September 1, 2024 | August 31, 2029 | MOK, SAMUEL C | reporter.nih.gov |
| Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,978,073 | July 1, 2023 | June 30, 2028 | VOKES, NATALIE | reporter.nih.gov |
| New Therapeutic Approaches for Stratified High-REST GBM Subtype | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,972,350 | December 1, 2021 | November 30, 2026 | MAJUMDER, SADHAN | reporter.nih.gov |
| Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,972,350 | April 15, 2021 | February 28, 2027 | CHEN, YIWEN | reporter.nih.gov |
| Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,971,553 | September 19, 2023 | August 31, 2028 | THOMPSON, TIMOTHY CHARLES | reporter.nih.gov |
| Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | NIH | National Cancer Institute | 2021 to 2025 | $1,970,730 | February 1, 2021 | January 31, 2027 | FUEYO, JUAN | reporter.nih.gov |
| Mechanisms of fasting-induced radioprotection of small intestinal epithelial cells | NIH | National Cancer Institute | 2023 to 2025 | $1,951,482 | June 1, 2023 | May 31, 2028 | PIWNICA-WORMS, HELEN M | reporter.nih.gov |
| Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,946,425 | February 15, 2023 | January 31, 2028 | HUTCHESON, KATHERINE ARNOLD | reporter.nih.gov |
| Health equity in fertility specialty care among cancer survivors | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $1,943,889 | June 28, 2023 | December 31, 2027 | RAUH-HAIN, JOSE ALEJANDRO | reporter.nih.gov |
| Therapeutic Targeting of NSD2 in Lung Adenocarcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,941,343 | June 1, 2023 | May 31, 2028 | MAZUR, PAWEL K. | reporter.nih.gov |
| Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation | NIH | National Cancer Institute | 2021 to 2025 | $1,931,122 | December 7, 2020 | November 30, 2025 | GAN, BOYI | reporter.nih.gov |
| Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,926,899 | July 15, 2023 | July 31, 2028 | LAI, STEPHEN Y | reporter.nih.gov |
| Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC) | NIH | National Cancer Institute | 2021 to 2023 | $1,925,971 | September 18, 2019 | November 30, 2024 | JOHNSON, FAYE | reporter.nih.gov |
| Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,921,637 | July 1, 2023 | June 30, 2028 | MAZUR, PAWEL K. | reporter.nih.gov |
| Targeting replication stress and homologous recombination repair mechanisms in HPV-positive and negative head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $1,921,017 | July 1, 2021 | April 30, 2027 | OSMAN, ABDULLAH ALI | reporter.nih.gov |
| Role of NSD3 in regulation of cancer pathogenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,917,587 | April 1, 2023 | March 31, 2028 | MAZUR, PAWEL K. | reporter.nih.gov |
| Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,917,273 | July 20, 2022 | June 30, 2027 | ORLOWSKI, ROBERT ZYGMUNT | reporter.nih.gov |
| RNase H2 is a novel therapeutic target in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,886,006 | July 1, 2021 | June 30, 2027 | LIN, SHIAW-YIH | reporter.nih.gov |
| Breaking down tumor immune privilege through targeted hypoxia reduction | NIH | National Cancer Institute | 2021 to 2024 | $1,883,414 | July 1, 2020 | June 30, 2025 | CURRAN, MICHAEL A. | reporter.nih.gov |
| A Genome Data Analysis Center Focused on Batch Effect Analysis and Data Integration | NIH | National Cancer Institute | 2021 to 2025 | $1,879,038 | September 22, 2021 | August 31, 2026 | AKBANI, REHAN | reporter.nih.gov |
| Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC) | NIH | National Cancer Institute | 2023 to 2025 | $1,877,904 | September 21, 2023 | August 31, 2028 | APARICIO, ANA | reporter.nih.gov |
| Statistical methods for genomic analysis of heterogeneous tumors | NIH | National Cancer Institute | 2022 to 2025 | $1,872,847 | July 8, 2022 | June 30, 2027 | WANG, WENYI | reporter.nih.gov |
| Molecular Determinants of Synaptic Plasticity in Chronic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,868,197 | August 15, 2017 | November 30, 2027 | PAN, HUI-LIN | reporter.nih.gov |
| Transcriptional and epigenetic basis of lung epithelial cell fate | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,860,726 | July 1, 2020 | December 31, 2023 | CHEN, JICHAO | reporter.nih.gov |
| Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML | NIH | National Cancer Institute | 2021 to 2024 | $1,860,616 | April 13, 2020 | March 31, 2025 | BHALLA, KAPIL | reporter.nih.gov |
| Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic | NIH | National Cancer Institute | 2025 | $1,847,485 | September 19, 2025 | August 31, 2029 | REZVANI, KATY | reporter.nih.gov |
| Improving Health Utilization and Quality of Life in Head and Neck Cancer Patients Undergoing Chemoradiation and their Family Caregivers | NIH | National Cancer Institute | 2021 to 2025 | $1,838,578 | September 15, 2020 | June 30, 2026 | MILBURY, KATHRIN | reporter.nih.gov |
| Development and Dissemination of Clinical CEST MRI Acquisition and Analysis Methods for Cancer Imaging Applications | NIH | National Cancer Institute | 2021 to 2023 | $1,838,448 | September 12, 2019 | August 31, 2024 | MA, JINGFEI | reporter.nih.gov |
| Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | NIH | National Cancer Institute | 2024 to 2025 | $1,834,300 | January 1, 2024 | December 31, 2028 | ROBINSON, JASON D | reporter.nih.gov |
| The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,829,056 | January 1, 2023 | December 31, 2027 | KOONG, ALBERT | reporter.nih.gov |
| Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors | NIH | National Cancer Institute | 2021 to 2025 | $1,826,936 | August 10, 2021 | July 31, 2026 | YAP, TIMOTHY ANTHONY | reporter.nih.gov |
| Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,826,936 | September 1, 2021 | August 31, 2026 | SKOULIDIS, FERDINANDOS | reporter.nih.gov |
| Rigorous and reproducible mutational analysis of the urinary exosomal DNA | NIH | National Cancer Institute | 2021 to 2023 | $1,825,912 | July 1, 2019 | June 30, 2025 | KALLURI, RAGHU | reporter.nih.gov |
| MD Anderson Sarcoma SPORE | NIH | National Cancer Institute | 2025 | $1,824,620 | August 19, 2025 | July 31, 2030 | GORLICK, RICHARD G. | reporter.nih.gov |
| Regulation of mesenchymal cells by epithelial Wnt ligands | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,824,465 | March 1, 2016 | December 31, 2023 | CHEN, JICHAO | reporter.nih.gov |
| Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,819,525 | June 4, 2021 | November 30, 2026 | SONG, MIN SUP | reporter.nih.gov |
| Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,819,525 | April 1, 2021 | March 31, 2027 | ZUO, XIANGSHENG | reporter.nih.gov |
| Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy | NIH | National Cancer Institute | 2022 to 2025 | $1,816,895 | July 22, 2022 | June 30, 2027 | LIN, CHUNRU | reporter.nih.gov |
| Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,813,775 | February 1, 2021 | January 31, 2027 | LIN, SHIAW-YIH | reporter.nih.gov |
| MicroRNA In Diabetic Nephropathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,812,837 | September 15, 2011 | June 30, 2025 | DANESH, FARHAD R | reporter.nih.gov |
| Signaling Mechanisms of Opioid-Induced Hyperalgesia and Tolerance | NIH | National Institute on Drug Abuse | 2022 to 2025 | $1,791,460 | March 1, 2017 | April 30, 2027 | PAN, HUI-LIN | reporter.nih.gov |
| A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,776,988 | April 1, 2020 | March 31, 2025 | LANG, FREDERICK F | reporter.nih.gov |
| Neural Mechanisms of Calcineurin Inhibitor-Induced Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,760,082 | August 1, 2020 | July 31, 2025 | PAN, HUI-LIN | reporter.nih.gov |
| Targeting Acquired Resistance in KRAS Driven Cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,736,422 | August 12, 2022 | July 31, 2027 | YAO, WANTONG | reporter.nih.gov |
| Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,734,793 | January 1, 2023 | December 31, 2027 | ZHAO, DI | reporter.nih.gov |
| Heterozygous KMT2D Loss and Medulloblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,730,741 | August 9, 2022 | July 31, 2027 | LEE, MIN GYU | reporter.nih.gov |
| Promoting remyelination in multiple sclerosis by simultaneously modulating myelin debris clearance and myelin lipid synthesis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,728,925 | July 15, 2022 | April 30, 2027 | HU, JIAN | reporter.nih.gov |
| Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development | NIH | National Cancer Institute | 2022 to 2025 | $1,727,878 | July 1, 2022 | June 30, 2027 | KADARA, HUMAM | reporter.nih.gov |
| UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science) | NIH | National Cancer Institute | 2021 to 2024 | $1,721,524 | September 3, 2020 | August 31, 2025 | KEYOMARSI, KHANDAN | reporter.nih.gov |
| Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi | NIH | National Cancer Institute | 2021 to 2024 | $1,720,846 | December 1, 2019 | February 28, 2025 | KURIE, JONATHAN M | reporter.nih.gov |
| Gene-Product Auto-Targeting to Tumor Vessels | NIH | National Cancer Institute | 2021 to 2025 | $1,707,137 | August 1, 2007 | April 30, 2027 | LI, SHULIN | reporter.nih.gov |
| Quantitative PET Imaging of Hepatocellular Carcinoma (HCC) | NIH | National Cancer Institute | 2021 to 2024 | $1,706,571 | September 22, 2020 | August 31, 2025 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Role of the pro-inflammatory omental microenvironment in ovarian cancer progression | NIH | National Cancer Institute | 2022 to 2025 | $1,700,150 | May 3, 2022 | April 30, 2027 | AU YEUNG, CHI LAM | reporter.nih.gov |
| DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | NIH | National Cancer Institute | 2021 to 2024 | $1,698,950 | December 1, 2019 | November 30, 2025 | NAVIN, NICHOLAS | reporter.nih.gov |
| Molecular basis of the NAADP-gated calcium release channel complexes | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,696,339 | September 15, 2018 | July 31, 2026 | YAN, JIUSHENG | reporter.nih.gov |
| A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | NIH | National Cancer Institute | 2022 to 2025 | $1,687,964 | March 21, 2022 | February 28, 2027 | LIU, HO-LING ANTHONY | reporter.nih.gov |
| U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer | NIH | National Cancer Institute | 2021 | $1,686,672 | September 22, 2017 | August 31, 2023 | BAST, ROBERT C | reporter.nih.gov |
| Analgesic Signaling in Drosophila | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,683,453 | June 15, 2022 | April 2, 2026 | GALKO, MICHAEL J | reporter.nih.gov |
| A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma | NIH | National Cancer Institute | 2022 to 2024 | $1,680,455 | January 1, 2019 | July 31, 2025 | PUDUVALLI, VINAY K | reporter.nih.gov |
| Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translation | NIH | National Cancer Institute | 2021 to 2024 | $1,665,253 | July 1, 2020 | June 30, 2026 | GAN, BOYI | reporter.nih.gov |
| Biodegradable Radiopaque Polymeric Scaffolds Loaded with Mesenchymal Stem Cells for Image-Guided Arteriovenous Fistula Maturation and Long-Term Patency | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,634,900 | April 15, 2022 | March 31, 2027 | MELANCON, MARITES PASUELO | reporter.nih.gov |
| Computational approaches for protein functional analysis using CRISPR screens | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,620,000 | September 15, 2020 | August 31, 2025 | XU, HAN | reporter.nih.gov |
| Pro-Drug Enolase Inhibitors in Precision Oncology | NIH | National Cancer Institute | 2021 to 2025 | $1,618,674 | February 8, 2021 | January 31, 2027 | MILLWARD, STEVEN W | reporter.nih.gov |
| Investigating the role of dysfunctional histone H3.3 in driving early neuronal development and pediatric high-grade gliomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,617,011 | June 1, 2021 | November 30, 2026 | HU, JIAN | reporter.nih.gov |
| Controlling the core airway mucin secretion machinery to prevent pathophysiology | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,611,504 | September 1, 2015 | March 31, 2024 | DICKEY, BURTON F | reporter.nih.gov |
| Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | NIH | National Center for Complementary & Integrative Health | 2023 to 2025 | $1,609,706 | February 24, 2023 | July 31, 2026 | MAMA, SCHEREZADE KELLY | reporter.nih.gov |
| UCHL5 as a regulator and therapeutic target in metastatic melanoma | NIH | National Cancer Institute | 2021 to 2024 | $1,608,800 | August 1, 2020 | April 30, 2026 | RAI, KUNAL | reporter.nih.gov |
| A Squirrel Monkey Model of Alzheimer’s Disease: Developing Behavioral, Blood, and CSF Biomarkers | NIH | National Institute on Aging | 2024 to 2025 | $1,605,066 | September 15, 2021 | May 31, 2027 | HOPKINS, WILLIAM D | reporter.nih.gov |
| Relationships between immunosenescence, brain aging biomarkers, and cognition across nonhuman primate species of differing lifespans | NIH | National Institute on Aging | 2024 to 2025 | $1,594,305 | September 15, 2024 | May 31, 2029 | MULHOLLAND, MICHELE M | reporter.nih.gov |
| Cancer Prevention Education: Student Research Experiences | NIH | National Cancer Institute | 2021 to 2025 | $1,588,289 | July 1, 1992 | May 31, 2029 | CHANG, SHINE | reporter.nih.gov |
| Signal Transduction by alphavbeta8 Integrin | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,572,120 | August 15, 2014 | November 30, 2025 | MCCARTY, JOSEPH H | reporter.nih.gov |
| Pathological flow-induced endothelial damage and plaque erosion | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,570,641 | July 15, 2019 | June 30, 2023 | ABE, JUN-ICHI | reporter.nih.gov |
| Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,551,678 | January 1, 2022 | December 31, 2026 | MCCARTY, JOSEPH H | reporter.nih.gov |
| Analyzing the Endothelial Cell-Expressed Prion Gene Prnd in Vascular Development | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,551,678 | December 1, 2021 | November 30, 2026 | MCCARTY, JOSEPH H | reporter.nih.gov |
| Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,538,451 | August 2, 2023 | July 31, 2028 | ZHANG, RUGANG | reporter.nih.gov |
| The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,536,429 | January 1, 2018 | December 31, 2024 | GIBBONS, DON LYNN | reporter.nih.gov |
| Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation | NIH | National Cancer Institute | 2023 to 2025 | $1,534,588 | June 12, 2023 | May 31, 2028 | SAWAKUCHI, GABRIEL OLIVEIRA | reporter.nih.gov |
| DNA damaging therapy and immune response in small cell lung cancer subtypes | NIH | National Cancer Institute | 2022 to 2025 | $1,521,891 | July 1, 2016 | March 31, 2027 | BYERS, LAUREN AVERETT | reporter.nih.gov |
| Role of p53 Missense Mutations on Tumorigenesis in Vivo | NIH | National Cancer Institute | 2021 to 2024 | $1,512,068 | February 4, 2020 | January 31, 2026 | LOZANO, GUILLERMINA | reporter.nih.gov |
| Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,496,161 | April 1, 2019 | March 31, 2024 | KOONG, ALBERT | reporter.nih.gov |
| Novel Biomarkers Predicting Blood Clots in Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,495,349 | September 19, 2023 | July 31, 2028 | AFSHAR-KHARGHAN, VAHID | reporter.nih.gov |
| Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $1,491,576 | September 2, 2020 | August 31, 2024 | SIKORA, ANDREW | reporter.nih.gov |
| Development of Pathology-activated Drugs for Treatment of Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $1,485,925 | September 20, 2022 | August 31, 2027 | GRACE, PETER M | reporter.nih.gov |
| Deciphering pathways involved in topoisomerase II turnover | NIH | National Cancer Institute | 2023 to 2025 | $1,483,748 | January 1, 2023 | December 31, 2027 | CHEN, JUNJIE | reporter.nih.gov |
| Elucidating mechanisms underlying replication checkpoint control | NIH | National Cancer Institute | 2023 to 2025 | $1,473,281 | June 16, 2023 | May 31, 2028 | CHEN, JUNJIE | reporter.nih.gov |
| Molecular Mechanisms of Bladder Cancer Immunometabolism | NIH | National Cancer Institute | 2023 to 2025 | $1,471,606 | March 1, 2023 | February 28, 2028 | YANG, LIUQING | reporter.nih.gov |
| A Combination Therapy to Treat Cancer-Related Fatigue | NIH | National Cancer Institute | 2021 to 2023 | $1,457,679 | December 1, 2018 | November 30, 2024 | YENNU, SRIRAM | reporter.nih.gov |
| Targeting ferroptosis in cancer therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,457,289 | March 1, 2023 | February 28, 2028 | GAN, BOYI | reporter.nih.gov |
| Regulation of chromatin organization and dynamics by INO80 | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,453,660 | May 1, 2015 | December 31, 2024 | BARTHOLOMEW, BLAINE | reporter.nih.gov |
| Role of UBR7, a novel H2BK120 E3 ubiquitin ligase, in suppression of breast cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,448,950 | April 1, 2020 | March 31, 2026 | RAI, KUNAL | reporter.nih.gov |
| Harnessing Aurora kinase inhibition‐induced cell death to enhance immunotherapy in HPV‐driven cancers | NIH | National Cancer Institute | 2021 to 2024 | $1,448,950 | April 1, 2020 | March 31, 2025 | JOHNSON, FAYE | reporter.nih.gov |
| Coordination of DNA repair and transcription by ubiquitin modification at DNA double strand breaks | NIH | National Cancer Institute | 2021 to 2024 | $1,448,950 | April 1, 2020 | March 31, 2026 | WANG, BIN | reporter.nih.gov |
| Platelets promote growth of ovarian cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,447,929 | August 1, 2013 | November 30, 2024 | AFSHAR-KHARGHAN, VAHID | reporter.nih.gov |
| Molecular Mechanism of long Noncoding RNAs in Phenylketonuria | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,444,963 | April 10, 2023 | January 31, 2028 | YANG, LIUQING | reporter.nih.gov |
| Efficacy and Safety of Rapid-Onset Opioids for Exertional Dyspnea in Cancer Patients | NIH | National Cancer Institute | 2021 to 2024 | $1,444,475 | January 1, 2020 | May 31, 2024 | HUI, DAVID | reporter.nih.gov |
| Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | NIH | National Cancer Institute | 2022 to 2025 | $1,418,567 | August 4, 2016 | March 31, 2027 | GREEN, MICHAEL RICHARD | reporter.nih.gov |
| Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,416,386 | January 1, 2023 | December 31, 2027 | MA, LI | reporter.nih.gov |
| Repurposing Glucosylceramide Synthase to Promote Mitochondrial Lethality and Potentiate an Anti-Tumor Immune Response in Triple-Negative Breast Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,411,915 | May 31, 2023 | April 30, 2028 | FAHRMANN, JOHANNES F | reporter.nih.gov |
| Role of Rho Kinase in Diabetic Nephropathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,411,344 | February 1, 2009 | June 30, 2025 | DANESH, FARHAD R | reporter.nih.gov |
| PEA15 IN DEVELOPMENT OF LIVER CANCER AND ITS THERAPEUTIC IMPLICATION | NIH | National Cancer Institute | 2021 to 2024 | $1,405,770 | February 6, 2020 | January 31, 2026 | LEE, JU-SEOG | reporter.nih.gov |
| Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,394,210 | September 19, 2023 | August 31, 2028 | HUFF, CHAD DANIEL | reporter.nih.gov |
| PAF-Remodeled DREAM Complex in Cancer and Regeneration | NIH | National Cancer Institute | 2021 to 2024 | $1,392,814 | March 9, 2015 | April 30, 2025 | PARK, JAE-IL | reporter.nih.gov |
| Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery | NIH | National Cancer Institute | 2023 to 2025 | $1,391,344 | May 1, 2023 | April 30, 2029 | COHEN, LORENZO | reporter.nih.gov |
| The Texas-Louisiana Alliance to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,390,069 | September 5, 2020 | June 30, 2025 | CHARI, SURESH T. | reporter.nih.gov |
| Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBM | NIH | National Cancer Institute | 2023 to 2025 | $1,386,369 | June 1, 2023 | May 31, 2028 | GOSWAMI, SANGEETA | reporter.nih.gov |
| Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,379,063 | February 1, 2023 | January 31, 2028 | YU, DIHUA | reporter.nih.gov |
| Deciphering Functional Consequences of Specific and Combinatorial Mutations in Protein Interaction Networks | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,377,340 | September 1, 2020 | April 15, 2024 | SAHNI, NIDHI | reporter.nih.gov |
| An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | NIH | National Cancer Institute | 2023 to 2025 | $1,371,191 | March 1, 2023 | February 29, 2028 | SHETH, RAHUL ANIL | reporter.nih.gov |
| Statistical Methods for Integration of Multiple Data Sources toward Precision Cancer Medicine | NIH | National Cancer Institute | 2022 to 2025 | $1,370,574 | June 1, 2022 | May 31, 2027 | NING, JING | reporter.nih.gov |
| Interrogating the Role of Bacterial Methyl-modifying Enzymes in Pathoadaptation and Host Epigenetic Interference in Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,368,607 | August 5, 2024 | July 31, 2029 | JOHNSTON, CHRISTOPHER D | reporter.nih.gov |
| Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $1,361,915 | June 15, 2021 | April 30, 2023 | PICKERING, CURTIS | reporter.nih.gov |
| Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation | NIH | National Cancer Institute | 2024 to 2025 | $1,357,965 | August 1, 2024 | July 31, 2029 | YANG, LIUQING | reporter.nih.gov |
| Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $1,357,029 | August 1, 2024 | July 31, 2029 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Prebiotic diet intervention to enhance the microbiome and immunotherapy response in melanoma | NIH | National Cancer Institute | 2024 to 2025 | $1,354,877 | August 15, 2024 | July 31, 2029 | DANIEL-MACDOUGALL, CARRIE | reporter.nih.gov |
| Studying metabolic stress signaling in renal cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,353,937 | June 1, 2014 | April 30, 2025 | GAN, BOYI | reporter.nih.gov |
| Bayesian Methods for Complex Precision Biotherapy Trials in Oncology | NIH | National Cancer Institute | 2021 to 2024 | $1,350,553 | September 15, 2021 | August 31, 2025 | THALL, PETER F | reporter.nih.gov |
| Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,349,677 | August 1, 2024 | July 31, 2028 | LEI, YU LEO | reporter.nih.gov |
| Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,344,600 | April 1, 2024 | March 31, 2029 | MSAOUEL, PAVLOS | reporter.nih.gov |
| Mechanisms of Epigenetic Plasticity in Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,344,471 | April 1, 2023 | March 31, 2028 | PAN, HUI-LIN | reporter.nih.gov |
| Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | NIH | National Cancer Institute | 2024 to 2025 | $1,344,092 | December 19, 2023 | November 30, 2028 | TWEARDY, DAVID JOHN | reporter.nih.gov |
| Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5 | NIH | National Cancer Institute | 2021 to 2023 | $1,342,792 | May 1, 2019 | June 30, 2024 | YU, DIHUA | reporter.nih.gov |
| Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,340,716 | August 1, 2024 | July 31, 2029 | CASCONE, TINA | reporter.nih.gov |
| Role of disparities and aging biomarkers in accelerated cardiac aging among adolescent and young adult cancer survivors | NIH | National Cancer Institute | 2024 to 2025 | $1,329,055 | July 10, 2024 | June 30, 2026 | HILDEBRANDT, MICHELLE A T | reporter.nih.gov |
| MDACC-PREDICT | NIH | National Cancer Institute | 2021 to 2022 | $1,327,977 | September 1, 2020 | August 31, 2025 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Metabolic basis of ARID1A-mutated ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,322,798 | August 1, 2022 | November 30, 2027 | ZHANG, RUGANG | reporter.nih.gov |
| Scientific Communication Advances Research Excellence (SCOARE) 2.0 | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,320,822 | September 19, 2017 | June 30, 2027 | CAMERON, CARRIE A. | reporter.nih.gov |
| Strategies for Personalizing Oxygen and support Therapies for dyspnea in Oncology | NIH | National Cancer Institute | 2024 to 2025 | $1,320,556 | May 1, 2024 | April 30, 2029 | HUI, DAVID | reporter.nih.gov |
| Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies | NIH | National Cancer Institute | 2021 to 2022 | $1,314,717 | July 1, 2018 | June 30, 2024 | MAITRA, ANIRBAN | reporter.nih.gov |
| Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events | NIH | National Cancer Institute | 2024 to 2025 | $1,314,238 | January 19, 2024 | December 31, 2028 | NAING, AUNG | reporter.nih.gov |
| Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,314,058 | March 1, 2023 | November 30, 2025 | QUARLES, CHRISTOPHER CHAD | reporter.nih.gov |
| Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,309,419 | July 1, 2024 | June 30, 2029 | COLBERT, LAUREN ELIZABETH | reporter.nih.gov |
| ERK mediated regulation of RbAp46/48 during female germ cell development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,303,327 | July 18, 2020 | April 30, 2025 | ARUR, SWATHI | reporter.nih.gov |
| Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,295,411 | August 16, 2016 | July 31, 2027 | PENG, GUANG | reporter.nih.gov |
| Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma | NIH | National Cancer Institute | 2024 to 2025 | $1,291,746 | July 5, 2024 | June 30, 2029 | JIANG, WEN | reporter.nih.gov |
| Translational Genomics and Precision Medicine in Cancer Training Program | NIH | National Cancer Institute | 2021 to 2025 | $1,268,840 | April 1, 2018 | August 31, 2029 | SEN, SUBRATA | reporter.nih.gov |
| Regulation of Overall Cell Numbers During Epithelial Tissue Homeostasis and Pathogenesis | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,263,600 | April 1, 2023 | March 31, 2028 | EISENHOFFER, GEORGE THOMAS | reporter.nih.gov |
| How age-dependent alterations in meiotic recombination cause chromosome mis-segregation in sperm | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,257,035 | July 15, 2019 | June 30, 2025 | COLE, FRANCESCA | reporter.nih.gov |
| Defining the landscape of bacterial-colonized microniches in tumors and their role in intratumoral heterogeneity. | NIH | National Cancer Institute | 2024 to 2025 | $1,247,680 | September 1, 2024 | August 31, 2029 | BULLMAN, SUSAN | reporter.nih.gov |
| Project Title: Low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC) | NIH | National Cancer Institute | 2024 to 2025 | $1,246,808 | September 25, 2025 | March 24, 2027 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| The role of membrane homoeostasis of neural stem cell and glioma stem cells in neural development and gliomagenesis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,240,371 | August 21, 2023 | May 31, 2028 | HU, JIAN | reporter.nih.gov |
| Adoptive T Cell Therapy for Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,237,671 | August 1, 2019 | July 31, 2025 | YEE, CASSIAN | reporter.nih.gov |
| Overcoming the triple threat to diversity in the health science workforce: empowering the next gen. | NIH | National Institute of General Medical Sciences | 2022 to 2024 | $1,235,754 | August 15, 2022 | May 31, 2025 | CHANG, SHINE | reporter.nih.gov |
| Regulation of tumor recurrence by stress activated neutrophils | NIH | National Cancer Institute | 2022 to 2025 | $1,231,723 | June 1, 2020 | January 31, 2026 | ZHANG, RUGANG | reporter.nih.gov |
| Impact of clonal hematopoiesis mutations on toxicity and outcomes following oncologic therapy | NIH | National Cancer Institute | 2021 to 2025 | $1,224,376 | September 10, 2021 | August 31, 2026 | NEAD, KEVIN THOMAS | reporter.nih.gov |
| Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology | NIH | National Cancer Institute | 2022 to 2025 | $1,213,626 | September 1, 2015 | March 31, 2027 | SOKOLOV, KONSTANTIN V | reporter.nih.gov |
| Bhlhe40 Regulation of T Cell Function During Cancer Immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,213,270 | June 1, 2024 | May 31, 2026 | GUBIN, MATTHEW M. | reporter.nih.gov |
| The Metabolic Basis of Cancer-Related Fatigue | NIH | National Cancer Institute | 2021 to 2023 | $1,207,591 | May 19, 2015 | June 30, 2025 | DANTZER, ROBERT | reporter.nih.gov |
| CRACD-controlled cell plasticity and small cell lung cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,202,413 | January 1, 2024 | December 31, 2028 | PARK, JAE-IL | reporter.nih.gov |
| Genetic and Molecular Definition of Histone Modifying Enzyme Functions | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,200,000 | April 1, 2019 | March 31, 2024 | DENT, SHARON Y. R. | reporter.nih.gov |
| Genetic analysis of innate immunity using C. elegans | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,198,605 | September 30, 2004 | August 31, 2027 | ABALLAY, ALEJANDRO | reporter.nih.gov |
| Integrative Brain Network-Based Analysis for Heterogeneous and Multimodal | NIH | National Institute of Mental Health | 2021 to 2023 | $1,195,453 | July 26, 2021 | June 30, 2025 | KUNDU, SUPRATEEK | reporter.nih.gov |
| The role of PTEN feedback mechanism in cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,194,750 | August 1, 2016 | May 31, 2028 | SONG, MIN SUP | reporter.nih.gov |
| Female Reproductive Tract Development in the mouse | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,176,000 | January 1, 1994 | May 31, 2024 | BEHRINGER, RICHARD R | reporter.nih.gov |
| Establishing the clinical utility of a consensus DSC-MRI Protocol | NIH | National Cancer Institute | 2023 to 2025 | $1,174,014 | March 1, 2022 | February 28, 2028 | QUARLES, CHRISTOPHER CHAD | reporter.nih.gov |
| Cytoplasmic cyclin E is an early event for progression to invasive breast cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,166,359 | February 1, 2018 | January 31, 2026 | KEYOMARSI, KHANDAN | reporter.nih.gov |
| Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs | NIH | National Cancer Institute | 2024 to 2025 | $1,144,229 | March 11, 2024 | February 28, 2029 | TORRES, KEILA ENITT | reporter.nih.gov |
| Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | NIH | National Cancer Institute | 2024 to 2025 | $1,144,052 | December 29, 2023 | November 30, 2028 | PARK, JAE-IL | reporter.nih.gov |
| Role of SETD5 in Chromatin Regulation and Tumorigenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,143,273 | April 1, 2019 | March 31, 2024 | MAZUR, PAWEL K. | reporter.nih.gov |
| REST-mediated regulation of opioid receptors in chronic pain mouse models | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,135,224 | July 1, 2020 | June 30, 2027 | MAJUMDER, SADHAN | reporter.nih.gov |
| Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell Carcinoma | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $1,121,874 | May 1, 2019 | April 30, 2023 | PICKERING, CURTIS | reporter.nih.gov |
| Restoring the Immunogenicity of Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,115,187 | July 1, 2024 | June 30, 2028 | LEI, YU LEO | reporter.nih.gov |
| Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual | NIH | National Cancer Institute | 2023 to 2025 | $1,107,751 | May 12, 2023 | April 30, 2027 | HUANG, XUELIN | reporter.nih.gov |
| Image Guided Cancer Therapy Training Program | NIH | National Cancer Institute | 2022 to 2025 | $1,095,142 | April 1, 2022 | March 31, 2027 | BROCK, KRISTY | reporter.nih.gov |
| Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | NIH | National Cancer Institute | 2023 to 2025 | $1,093,197 | January 18, 2023 | December 31, 2027 | WANG, GUOCAN | reporter.nih.gov |
| Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC. | NIH | National Cancer Institute | 2023 to 2025 | $1,093,197 | May 17, 2023 | April 30, 2028 | SKOULIDIS, FERDINANDOS | reporter.nih.gov |
| Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure. | NIH | National Cancer Institute | 2023 to 2025 | $1,093,197 | April 1, 2023 | March 31, 2028 | DAHER, MAY | reporter.nih.gov |
| Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,093,197 | May 2, 2023 | April 30, 2028 | SKOULIDIS, FERDINANDOS | reporter.nih.gov |
| Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors | NIH | National Cancer Institute | 2023 to 2025 | $1,093,197 | July 1, 2023 | June 30, 2028 | NURIEVA, ROZA INSAFETDINOVNA | reporter.nih.gov |
| Dyadic yoga Program for Patients with Lung Cancer Undergoing Radiotherapy and their Family Caregivers | NIH | National Cancer Institute | 2021 to 2024 | $1,093,057 | August 1, 2024 | July 31, 2026 | MILBURY, KATHRIN | reporter.nih.gov |
| The molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,090,680 | February 1, 2019 | January 31, 2025 | ZHANG, JIANJUN | reporter.nih.gov |
| ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | NIH | National Cancer Institute | 2022 to 2025 | $1,087,515 | March 8, 2022 | February 28, 2028 | YUN, JIHYE | reporter.nih.gov |
| Incentive salience and the neuropsychological underpinnings of cue-induced smoking relapse | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,085,138 | July 15, 2012 | April 30, 2026 | VERSACE, FRANCESCO | reporter.nih.gov |
| Immuno-inflammatory Response Non-coding RNAs as Predictors of HPV Status & Outcome of Oropharyngeal Cancer Patients | NIH | National Cancer Institute | 2021 to 2024 | $1,084,699 | December 1, 2019 | November 30, 2025 | LI, GUOJUN | reporter.nih.gov |
| Elucidating and targeting subtype-specific driver in pancreatic cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,083,360 | April 1, 2019 | March 31, 2024 | YING, HAOQIANG | reporter.nih.gov |
| Characterizing heterochromatin dysfunction as a driving alteration in cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,083,360 | July 1, 2019 | June 30, 2025 | HUSE, JASON | reporter.nih.gov |
| INVESTIGATING TUMOR INITIATION AND INVASION IN PREMALIGNANT BREAST CANCER WITH SPATIAL SINGLE CELL GENOMICS | NIH | National Cancer Institute | 2021 to 2023 | $1,083,360 | June 12, 2019 | May 31, 2025 | NAVIN, NICHOLAS | reporter.nih.gov |
| Interrogating the Spatial and Functional Relevance of Microbes in Pancreatic Cancer and Metastasis | NIH | National Cancer Institute | 2024 to 2025 | $1,078,684 | August 1, 2024 | July 31, 2029 | MCALLISTER, FLORENCIA | reporter.nih.gov |
| Determine the Role of Histone Methyltransferase ASH1L in Metastatic Prostate Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,075,398 | September 18, 2024 | August 31, 2029 | ZHAO, DI | reporter.nih.gov |
| Mechanisms associated with organotropic metastasis | NIH | National Cancer Institute | 2021 to 2022 | $1,073,863 | July 1, 2021 | June 30, 2023 | KALLURI, RAGHU | reporter.nih.gov |
| Wnt/?-catenin Signaling in Pancreatic Oncogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,072,598 | September 14, 2017 | May 31, 2024 | MAITRA, ANIRBAN | reporter.nih.gov |
| Non-coding RNA functions in tumor metastasis | NIH | National Cancer Institute | 2021 to 2023 | $1,065,600 | August 1, 2012 | November 30, 2024 | MA, LI | reporter.nih.gov |
| Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,065,397 | June 5, 2019 | November 30, 2025 | GEORGE, GOLDY C | reporter.nih.gov |
| Integrative approaches for decoding the function and regulation of unconventional RNA translation | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,060,306 | September 10, 2019 | June 30, 2025 | CHEN, YIWEN | reporter.nih.gov |
| Membrane Permeant Peptides for Imaging Cell Function | NIH | National Eye Institute | 2021 to 2022 | $1,055,993 | July 1, 1999 | August 31, 2024 | PIWNICA-WORMS, DAVID | reporter.nih.gov |
| Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,049,838 | May 2, 2024 | April 30, 2028 | SHEPHERD, ANDREW JOHN | reporter.nih.gov |
| Targeting the gut microbiome to inhibit melanoma lymph node metastases | NIH | National Cancer Institute | 2024 to 2025 | $1,045,724 | May 1, 2024 | May 30, 2028 | WARGO, JENNIFER A. | reporter.nih.gov |
| Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | NIH | National Cancer Institute | 2022 to 2025 | $1,041,612 | April 18, 2022 | March 31, 2027 | WEHNER, MACKENZIE RACHEL | reporter.nih.gov |
| Role of PRMT7 in Genomic Imprinting | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,041,417 | August 17, 2023 | May 31, 2027 | CHEN, TAIPING | reporter.nih.gov |
| Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,041,302 | December 1, 2015 | January 31, 2027 | ZHANG, RUGANG | reporter.nih.gov |
| Single Cell Spatial Analysis in Tissue | NIH | National Cancer Institute | 2021 to 2024 | $1,033,540 | September 9, 2020 | August 31, 2025 | BURKS, JARED KYLE | reporter.nih.gov |
| Development and Validation of a CSF Liquid Biopsy for Molecular Characterization and Monitoring of Patients with Central Nervous System Tumors | NIH | National Cancer Institute | 2021 to 2024 | $1,025,657 | September 11, 2020 | August 31, 2025 | BALLESTER, LEOMAR Y | reporter.nih.gov |
| Lymphedema Prevention Through Immediate Lymphatic Reconstruction | NIH | National Cancer Institute | 2024 to 2025 | $1,023,990 | August 1, 2024 | July 31, 2026 | SCHAVERIEN, MARK V | reporter.nih.gov |
| Reversing effector-to-memory transition at ARTi to impact the HIV reservoir towards ART-free control | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,016,951 | September 1, 2025 | August 31, 2030 | VILLINGER, FRANCOIS J | reporter.nih.gov |
| Proteostasis Reprogramming in Mutant KRAS-Driven Cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,016,261 | December 1, 2022 | May 31, 2028 | CHEN, XI | reporter.nih.gov |
| miR-155 targeted therapeutics for precision medicine in lung cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,014,215 | August 3, 2018 | July 31, 2024 | CALIN, GEORGE A. | reporter.nih.gov |
| New data science approaches to visualize and understand the impact of the microbiome on risk of graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,012,500 | April 1, 2022 | February 28, 2027 | PETERSON, CHRISTINE B | reporter.nih.gov |
| Cancer Curricular Advances for Research and Education (Cancer CARE) | NIH | National Cancer Institute | 2022 to 2025 | $1,009,590 | August 1, 2022 | July 31, 2027 | CHANG, SHINE | reporter.nih.gov |
| Anatomical Modeling to Improve the Precision of Image Guided Liver Ablation | NIH | National Cancer Institute | 2021 to 2023 | $999,364 | September 1, 2019 | August 31, 2025 | BROCK, KRISTY | reporter.nih.gov |
| Reproductive tract organ development and differentiation | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $998,141 | July 19, 2024 | April 30, 2029 | BEHRINGER, RICHARD R | reporter.nih.gov |
| Noncanonical roles of Bim in heat shock-induced cell death | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $980,244 | August 15, 2024 | May 31, 2028 | BRATTON, SHAWN B | reporter.nih.gov |
| Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) program | NIH | National Cancer Institute | 2023 to 2025 | $969,906 | September 1, 2023 | August 31, 2028 | MELANCON, MARITES PASUELO | reporter.nih.gov |
| Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $959,309 | July 1, 2023 | June 30, 2028 | ESCHWEILER, SIMON | reporter.nih.gov |
| Methods Training for Comparative Effectiveness Research in Cancer | NIH | National Cancer Institute | 2023 to 2025 | $953,672 | September 21, 2023 | August 31, 2028 | SUAREZ-ALMAZOR, MARIA E | reporter.nih.gov |
| Endothelial-to-osteoblast transition in prostate cancer bone metastasis | NIH | National Cancer Institute | 2021 to 2023 | $942,760 | April 1, 2013 | July 31, 2025 | LIN, SUE-HWA | reporter.nih.gov |
| Exploring Collateral Lethality for Development of Cancer Therapeutics | NIH | National Cancer Institute | 2021 to 2022 | $938,366 | April 9, 2018 | March 31, 2024 | DEPINHO, RONALD ANTHONY | reporter.nih.gov |
| Regulation of RNA polymerase II pausing and directionality by ATP-dependent chromatin remodelers | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $914,512 | April 15, 2019 | September 30, 2023 | BARTHOLOMEW, BLAINE | reporter.nih.gov |
| Defining pro-metastatic drivers in the pancreatic cancer tumor microenvironment | NIH | National Cancer Institute | 2024 to 2025 | $904,617 | September 1, 2024 | August 31, 2029 | KIM, MICHAEL PAUL | reporter.nih.gov |
| Nikon CSU W1 SoRa Super Resolution Spinning Disk Confocal Microscope with Photo-Stimulation and Photo-Ablation | NIH | Office of the Director, National Institutes of Health | 2024 | $897,557 | May 1, 2024 | April 30, 2025 | PAULUCCI-HOLTHAUZEN, ADRIANA | reporter.nih.gov |
| Role of Quaking gene in regulating the niche-independent stemness of glioma stem cells | NIH | National Cancer Institute | 2021 to 2022 | $890,670 | December 1, 2017 | November 30, 2023 | HU, JIAN | reporter.nih.gov |
| Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilities | NIH | National Cancer Institute | 2024 to 2025 | $886,305 | March 26, 2021 | August 31, 2027 | GUARNERIO, JLENIA | reporter.nih.gov |
| Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy | NIH | National Cancer Institute | 2022 to 2024 | $886,207 | July 20, 2022 | June 30, 2028 | YEE, CASSIAN | reporter.nih.gov |
| Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy | NIH | National Cancer Institute | 2023 to 2025 | $879,858 | March 1, 2020 | March 31, 2026 | ENDERLING, HEIKO | reporter.nih.gov |
| The E2F1 Post-Translational Modification Code | NIH | National Cancer Institute | 2021 to 2022 | $879,836 | August 1, 2018 | January 31, 2024 | JOHNSON, DAVID G. | reporter.nih.gov |
| (PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome | NIH | National Cancer Institute | 2021 to 2022 | $878,518 | September 20, 2018 | August 31, 2024 | WARGO, JENNIFER A. | reporter.nih.gov |
| Strategies for Persistent Agitated Delirium in Palliative Care | NIH | National Cancer Institute | 2021 to 2022 | $878,205 | January 1, 2019 | December 31, 2023 | HUI, DAVID | reporter.nih.gov |
| A phospho-switch in delta-catenin: relationship to PDZ-domain proteins and neuron development | NIH | National Institute of Mental Health | 2021 to 2022 | $876,384 | September 1, 2018 | May 31, 2024 | MCCREA, PIERRE D | reporter.nih.gov |
| Characterization of the cellular mechanisms of radiation induced brain necrosis for clinical intervention | NIH | National Cancer Institute | 2021 to 2025 | $870,933 | August 2, 2021 | July 31, 2027 | GROSSHANS, DAVID R | reporter.nih.gov |
| Elucidating Human Leukemia and T Cell Interactions within the Tumor Microenvironment | NIH | National Cancer Institute | 2021 to 2024 | $870,112 | April 1, 2021 | March 31, 2026 | BACHIREDDY, PAVAN | reporter.nih.gov |
| Activating p53 for colorectal cancer prevention | NIH | National Cancer Institute | 2021 to 2023 | $833,467 | June 12, 2018 | May 31, 2024 | WU, XIANGWEI | reporter.nih.gov |
| RISE: Reducing Cancer and HIV Stigma through Empowerment | NIH | National Cancer Institute | 2025 | $825,966 | September 4, 2025 | August 31, 2030 | LU, QIAN | reporter.nih.gov |
| Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $818,484 | May 21, 2018 | April 30, 2024 | WATOWICH, STEPHANIE S | reporter.nih.gov |
| Development of large-scale composite null hypothesis testing approaches to perform translational genetics analyses | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $817,500 | September 15, 2024 | July 31, 2029 | SUN, RYAN | reporter.nih.gov |
| Dissecting the role of DNA methylation in controlling retrotransposons and governing adult stem cell fates | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $817,500 | August 1, 2024 | May 31, 2029 | GE, YEJING | reporter.nih.gov |
| Mechanism of innate immune activation by intestinal distension | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $817,499 | April 1, 2024 | August 31, 2025 | ABALLAY, ALEJANDRO | reporter.nih.gov |
| Bayesian neurobehavioral phenotyping: from mechanism identification to personalized neuromodulation treatments | NIH | National Institute on Drug Abuse | 2024 to 2025 | $816,604 | September 15, 2024 | August 31, 2027 | VERSACE, FRANCESCO | reporter.nih.gov |
| Building a Diverse Biomedical Workforce Through Communication Across Difference | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $814,059 | July 18, 2019 | June 30, 2025 | CAMERON, CARRIE A. | reporter.nih.gov |
| Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2022 to 2024 | $811,452 | July 18, 2019 | January 31, 2026 | ZHANG, RUGANG | reporter.nih.gov |
| A Functional Analysis of Arginine Methylation | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $810,000 | September 1, 2024 | July 31, 2029 | BEDFORD, MARK T. | reporter.nih.gov |
| Role of E3 Ubiquitin ligase RNF133 in T cell function and tolerance | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $800,000 | January 1, 2019 | December 31, 2024 | NURIEVA, ROZA INSAFETDINOVNA | reporter.nih.gov |
| REST-mediated epigenomic and transcriptomic signatures in neuropathic pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $791,971 | September 15, 2019 | July 31, 2024 | MAJUMDER, SADHAN | reporter.nih.gov |
| Colorectal Cancer Molecular Subtype Assay Development and Validation | NIH | National Cancer Institute | 2021 to 2023 | $787,854 | September 21, 2018 | August 31, 2025 | MARU, DIPEN M. | reporter.nih.gov |
| Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing Data | NIH | National Cancer Institute | 2021 to 2022 | $773,222 | September 1, 2020 | May 31, 2024 | CHEN, KEN | reporter.nih.gov |
| Nanoparticle- Infused Radiopaque Absorbable Medical Device | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $772,616 | September 1, 2018 | June 30, 2024 | MELANCON, MARITES PASUELO | reporter.nih.gov |
| OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH | NIH | National Cancer Institute | 2021 to 2023 | $768,342 | September 23, 2019 | September 22, 2024 | BROWN, POWEL | reporter.nih.gov |
| Viral Replication Pathways During Oral Tumorigenesis and Response to Therapy | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $765,653 | January 1, 2018 | December 31, 2023 | SPIOTTO, MICHAEL T | reporter.nih.gov |
| Multi-parametric MRI Assessment of Brain Connectivity and Spectroscopic Biomarkers in Patients with a Substance Use Disorder | NIH | National Institute on Drug Abuse | 2021 to 2024 | $762,330 | September 1, 2020 | August 31, 2025 | TAYLOR, BRIAN ALLEN | reporter.nih.gov |
| Deciphering the role of GFPT2 in radiation-induced cardiovascular disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $760,982 | August 1, 2025 | May 31, 2029 | ABE, JUN-ICHI | reporter.nih.gov |
| Gender differences in Standard Research E-Cigarette (SREC) products use, acceptability, reinforcement, and nicotine dependence symptoms | NIH | National Institute on Drug Abuse | 2021 | $759,811 | September 30, 2018 | August 31, 2024 | ROBINSON, JASON D | reporter.nih.gov |
| Improving decision-making in patients with resectable melanoma and pre-existing autoimmune disease considering immune checkpoint inhibition | NIH | National Cancer Institute | 2021 to 2024 | $758,305 | April 16, 2020 | March 31, 2026 | LOPEZ-OLIVO, MARIA DE LOS ANGELES | reporter.nih.gov |
| Baboon model of chemotherapy-related cognitive impairment and accelerated aging | NIH | National Institute on Aging | 2022 to 2025 | $756,142 | August 15, 2022 | July 31, 2027 | MULHOLLAND, MICHELE M | reporter.nih.gov |
| Developing a Decision Tool for Chemotherapy in Older Women with Early Stage Breast Cancer | NIH | National Cancer Institute | 2021 to 2024 | $751,731 | July 1, 2019 | January 31, 2026 | KARUTURI, MEGHAN SRI | reporter.nih.gov |
| A novel PARP inhibitor PET tracer for breast cancer | NIH | National Cancer Institute | 2021 to 2023 | $747,506 | March 17, 2021 | February 28, 2025 | LIN, LILIE LEMING | reporter.nih.gov |
| Functional characterization of novel oncogenic loci driving progression and immune response in gastrointestinal cancer | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | September 1, 2021 | August 31, 2026 | LO, YUAN-HUNG | reporter.nih.gov |
| Genetics and Biology of Metastatic Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2022 | $746,515 | September 1, 2018 | August 31, 2023 | DEPINHO, RONALD ANTHONY | reporter.nih.gov |
| TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | NIH | National Cancer Institute | 2024 to 2025 | $741,150 | April 5, 2024 | March 31, 2029 | BASAR, RAFET | reporter.nih.gov |
| Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic Carcinoma | NIH | National Cancer Institute | 2024 to 2025 | $741,150 | August 1, 2024 | July 31, 2029 | FERRAROTTO, RENATA | reporter.nih.gov |
| Elucidating the role of support signaling in promoting minimal residual disease in mouse models of oncogene-driven lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $740,877 | February 1, 2020 | June 30, 2027 | VAISHNAVI, ARIA | reporter.nih.gov |
| Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications | NIH | National Cancer Institute | 2021 to 2023 | $740,334 | December 6, 2018 | July 31, 2023 | SHIH, YA-CHEN TINA | reporter.nih.gov |
| Ontology-based aPplications of mUlti-discipLinary knowlEdge on orodeNtal Conditions and outcomEs (OPULENCE) | NIH | National Institute of Dental & Craniofacial Research | 2025 | $736,507 | August 1, 2025 | May 31, 2030 | MORENO, AMY CATHERINE | reporter.nih.gov |
| Harvard MD Anderson Collaborative to Reduce LyMphatic MOrbidity in Head and Neck Cancer with Artificial Intelligence (HARMONiC-AI) | NIH | National Institute of Dental & Craniofacial Research | 2025 | $732,513 | April 8, 2025 | January 31, 2030 | FULLER, CLIFTON DAVID | reporter.nih.gov |
| Pre-metastatic Omental Niche Formation in Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $727,651 | April 1, 2018 | March 31, 2025 | NAORA, HONAMI | reporter.nih.gov |
| Validation of Critical 1q21 Vulnerabilities in Multiple Myeloma | NIH | National Cancer Institute | 2021 to 2022 | $726,654 | January 1, 2018 | December 31, 2023 | COLLA, SIMONA | reporter.nih.gov |
| PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain | NIH | National Cancer Institute | 2021 to 2023 | $726,198 | May 22, 2018 | April 30, 2025 | GRACE, PETER M | reporter.nih.gov |
| Define redundant functions of H2AX and NBS1 in DNA repair | NIH | National Cancer Institute | 2021 to 2022 | $724,680 | January 25, 2017 | December 31, 2023 | CHEN, JUNJIE | reporter.nih.gov |
| MSC-Derived Exosomes and MicroRNA in Glioma Therapy | NIH | National Cancer Institute | 2021 to 2022 | $724,680 | December 11, 2017 | November 30, 2023 | LANG, FREDERICK F | reporter.nih.gov |
| 53BP1-dependent pathway in DNA repair | NIH | National Cancer Institute | 2021 to 2022 | $724,680 | June 14, 2017 | May 31, 2024 | CHEN, JUNJIE | reporter.nih.gov |
| Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and Application | NIH | National Cancer Institute | 2021 to 2022 | $724,680 | July 5, 2018 | June 30, 2024 | LI, LIANG | reporter.nih.gov |
| Role of KMT2D and aberrant enhancers in modulating tumor microenvironment in melanoma | NIH | National Cancer Institute | 2021 to 2022 | $724,680 | August 1, 2018 | July 31, 2024 | RAI, KUNAL | reporter.nih.gov |
| Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling | NIH | National Cancer Institute | 2021 to 2022 | $724,190 | April 1, 2018 | March 31, 2024 | MOGHADDAM, SEYED JAVAD MIRHASSANI | reporter.nih.gov |
| Medium-chain acyl-coenzyme A dehydrogenase as an essential feeder of glioblastoma multiforme | NIH | National Cancer Institute | 2021 to 2022 | $721,914 | February 1, 2018 | January 31, 2024 | DRAETTA, GIULIO FRANCESCO | reporter.nih.gov |
| Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial | NIH | National Cancer Institute | 2023 to 2024 | $721,527 | September 20, 2023 | August 31, 2025 | SYMMANS, WILLIAM F | reporter.nih.gov |
| Mechanism of RAD51C fork protection and environmental carcinogenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $720,000 | September 15, 2018 | May 31, 2025 | SCHLACHER, KATHARINA | reporter.nih.gov |
| MD Anderson Summer Program in Cancer Research (SPCR) | NIH | National Cancer Institute | 2021 to 2025 | $717,784 | August 11, 2014 | March 31, 2030 | CHANDRA, JOYA | reporter.nih.gov |
| Optimization and Evaluation of Anatomical Models of Liver Radiation Response | NIH | National Cancer Institute | 2021 to 2022 | $717,615 | July 3, 2018 | June 30, 2025 | BROCK, KRISTY | reporter.nih.gov |
| Genomics of HCC in the Hispanic population of Texas | NIH | National Cancer Institute | 2021 to 2022 | $714,156 | April 1, 2018 | March 31, 2024 | BERETTA, LAURA | reporter.nih.gov |
| Statistical methods and tools for cancer risk prediction in families with germline mutations in TP53 | NIH | National Cancer Institute | 2021 to 2022 | $710,211 | April 1, 2019 | March 31, 2024 | WANG, WENYI | reporter.nih.gov |
| Establishing the Validity of Brain Tumor Perfusion Imaging | NIH | National Cancer Institute | 2023 to 2024 | $707,892 | July 3, 2017 | June 30, 2027 | QUARLES, CHRISTOPHER CHAD | reporter.nih.gov |
| BK channel regulation by auxiliary LRR proteins | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $700,000 | August 1, 2012 | May 31, 2024 | YAN, JIUSHENG | reporter.nih.gov |
| Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | NIH | National Center for Complementary & Integrative Health | 2023 to 2025 | $699,840 | April 1, 2023 | December 31, 2025 | CHO, DALNIM | reporter.nih.gov |
| Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer | NIH | National Cancer Institute | 2025 | $697,763 | February 1, 2025 | January 31, 2030 | JOHNSTON, CHRISTOPHER D | reporter.nih.gov |
| Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2025 | $695,004 | April 1, 2025 | March 31, 2030 | HEYMACH, JOHN V. | reporter.nih.gov |
| Regulation of Cell Turnover During Epithelial Tissue Homeostasis | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $694,914 | April 1, 2018 | March 31, 2023 | EISENHOFFER, GEORGE THOMAS | reporter.nih.gov |
| Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $692,580 | March 1, 2018 | March 31, 2024 | KIM, BETTY | reporter.nih.gov |
| Targeting mitochondrial complex I in acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2022 | $688,765 | June 14, 2019 | June 30, 2022 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| Machine learning for identifying antigen-antibody interactions from massive sequencing data | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $685,566 | March 1, 2025 | February 28, 2030 | WANG, TAO | reporter.nih.gov |
| Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture | NIH | National Cancer Institute | 2024 to 2025 | $685,239 | July 7, 2021 | February 28, 2027 | KREBS, SIMONE | reporter.nih.gov |
| Dynamic Prediction of Renal Failure Using Longitudinal Prognostic Information among Patients with Chronic Kidney Disease and Kidney Transplant | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $681,111 | April 10, 2019 | March 31, 2024 | LI, LIANG | reporter.nih.gov |
| Together stronger: A family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers | NIH | National Cancer Institute | 2025 | $680,600 | September 19, 2025 | August 31, 2030 | CHO, DALNIM | reporter.nih.gov |
| Replication fork protection and innate immune response | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $680,400 | September 1, 2024 | June 30, 2028 | WANG, BIN | reporter.nih.gov |
| Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | NIH | National Cancer Institute | 2025 | $676,584 | April 1, 2025 | March 31, 2030 | NAVIN, NICHOLAS | reporter.nih.gov |
| Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $675,862 | September 30, 2020 | August 31, 2025 | SHEPHERD, ANDREW JOHN | reporter.nih.gov |
| Effects of biologic and targeted therapies for rheumatoid arthritis on cancer outcomes | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2023 | $674,665 | July 23, 2021 | June 30, 2025 | SUAREZ-ALMAZOR, MARIA E | reporter.nih.gov |
| Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE | NIH | National Cancer Institute | 2022 | $664,838 | September 2, 2009 | August 31, 2023 | LOGOTHETIS, CHRISTOPHER J. | reporter.nih.gov |
| Supporting Tobacco-Related Ongoing Education and Research (STRONGER) Scholar Program | NIH | National Institute on Drug Abuse | 2024 to 2025 | $663,245 | April 1, 2024 | March 31, 2029 | REITZEL, LORRAINE R | reporter.nih.gov |
| Single-use Microfluidic Device for Radiopharmaceutical Production | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $663,092 | March 1, 2025 | February 28, 2029 | MANNING, HENRY CHARLES | reporter.nih.gov |
| Multi-Site Development & Evaluation of a Quantitative 3D Hyperpolarized C-13 MRI Clinical Prostate Cancer Exam | NIH | National Cancer Institute | 2021 | $649,183 | March 1, 2017 | February 28, 2025 | BANKSON, JAMES A | reporter.nih.gov |
| Epigenetic regulation of thrombopoiesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $648,000 | January 1, 2020 | December 31, 2024 | SANTOS, MARGARIDA | reporter.nih.gov |
| Targeted Hyperpolarized Molecular Beacons for Colorectal Cancer Detection | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $648,000 | September 30, 2021 | July 31, 2025 | BHATTACHARYA, PRATIP K. | reporter.nih.gov |
| Molecular mechanisms regulating TLR signaling and inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $639,843 | August 21, 2020 | January 31, 2022 | SUN, SHAO-CONG | reporter.nih.gov |
| The ontogeny and function of CD8 T cells in lung cancer | NIH | National Cancer Institute | 2023 to 2025 | $624,078 | February 1, 2021 | January 31, 2026 | SCHENKEL, JASON M. | reporter.nih.gov |
| A Randomized Controlled Trial of Mail-Self Stamped HPV Testing to Increase Cervical Cancer Screening Participation Among Minority/Underserved Women in an Integrated Safety Net Healthcare System | NIH | National Institute on Minority Health and Health Disparities | 2023 | $622,876 | April 16, 2019 | October 30, 2025 | MONTEALEGRE, JANE R | reporter.nih.gov |
| Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy | NIH | National Cancer Institute | 2025 | $616,715 | August 11, 2025 | July 31, 2030 | KIM, BETTY | reporter.nih.gov |
| Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | NIH | National Cancer Institute | 2025 | $616,495 | March 1, 2025 | February 28, 2030 | FAHRMANN, JOHANNES F | reporter.nih.gov |
| Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $600,434 | April 1, 2024 | February 28, 2029 | SHUKLA, SACHET ASHOK | reporter.nih.gov |
| Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA1/2 carriers | NIH | National Cancer Institute | 2025 | $597,289 | July 9, 2025 | June 30, 2027 | BEDROSIAN, ISABELLE | reporter.nih.gov |
| Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches | NIH | National Cancer Institute | 2021 | $596,334 | September 5, 2017 | August 31, 2024 | LIN, STEVEN HSESHENG | reporter.nih.gov |
| Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and Cancer | NIH | National Cancer Institute | 2021 | $595,717 | April 4, 2018 | March 31, 2022 | MAITRA, ANIRBAN | reporter.nih.gov |
| Targeting regenerative reprogramming in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $585,188 | September 1, 2024 | August 31, 2028 | ALONSO MARTINEZ, SALVADOR | reporter.nih.gov |
| Photon Counting Detector MicroCT | NIH | Office of the Director, National Institutes of Health | 2021 | $585,000 | April 15, 2021 | October 14, 2023 | LAYMAN, RICK ROBERT | reporter.nih.gov |
| Targeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC) | NIH | National Cancer Institute | 2021 to 2025 | $584,885 | September 21, 2021 | August 31, 2026 | NILSSON, MONIQUE B | reporter.nih.gov |
| Regulation of Mitochondrial Respiration in Diabetic Kidney Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $579,097 | July 1, 2025 | March 31, 2030 | DANESH, FARHAD R | reporter.nih.gov |
| Endogenous Circular RNAs limit abemaciclib anti tumor immune responses | NIH | National Cancer Institute | 2025 | $567,059 | March 17, 2025 | February 28, 2030 | GUARNERIO, JLENIA | reporter.nih.gov |
| Revisiting Antiangiogenic Therapy to Target Hormone-Sensitive Prostate Cancer Metabolism | NIH | National Cancer Institute | 2023 | $566,917 | May 12, 2023 | January 31, 2024 | FRIGO, DANIEL EDWARD | reporter.nih.gov |
| Study of a new driver and therapeutic vulnerability of bone metastasis | NIH | National Cancer Institute | 2025 | $564,695 | June 10, 2025 | May 31, 2030 | MA, LI | reporter.nih.gov |
| Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC) | NIH | National Cancer Institute | 2021 | $559,976 | September 30, 2017 | August 31, 2022 | MAITRA, ANIRBAN | reporter.nih.gov |
| Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC | NIH | National Cancer Institute | 2021 | $551,067 | August 1, 2017 | July 31, 2022 | HEYMACH, JOHN V. | reporter.nih.gov |
| Maintenance of genome stability in 3D | NIH | National Cancer Institute | 2025 | $544,454 | July 3, 2024 | June 30, 2026 | GAUTIER, JEAN | reporter.nih.gov |
| Role of targeting ATPases BRG1/BRM in therapy of AML | NIH | National Cancer Institute | 2025 | $542,663 | April 11, 2025 | March 31, 2030 | FISKUS, WARREN CAMPBELL | reporter.nih.gov |
| Delivery optimization of a transarterial ablative therapy | NIH | National Cancer Institute | 2025 | $536,836 | March 15, 2025 | February 28, 2030 | FUENTES, DAVID | reporter.nih.gov |
| Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer | NIH | National Cancer Institute | 2022 | $536,764 | March 1, 2022 | December 9, 2022 | UENO, NAOTO T. | reporter.nih.gov |
| TCR-antigen foundation model to empower TCR-based diagnostics and therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $528,157 | September 1, 2025 | August 31, 2030 | WANG, TAO | reporter.nih.gov |
| Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort | NIH | National Cancer Institute | 2025 | $525,013 | September 1, 2025 | August 31, 2030 | OSTRIN, EDWIN JUSTIN | reporter.nih.gov |
| Proteotoxic Metabolites in Genome Instability and Disease | NIH | National Cancer Institute | 2025 | $524,400 | December 1, 2024 | November 30, 2029 | KARRAS, GEORGIOS | reporter.nih.gov |
| Genetics of Graft-versus-Host Disease | NIH | National Cancer Institute | 2021 to 2022 | $522,214 | August 8, 2018 | July 31, 2024 | AFSHAR-KHARGHAN, VAHID | reporter.nih.gov |
| Deciphering the role of cancer pain-associated neuronal activity in driving malignancies | NIH | National Cancer Institute | 2025 | $513,127 | September 9, 2025 | August 31, 2030 | PAN, YUAN | reporter.nih.gov |
| Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling | NIH | National Cancer Institute | 2021 | $500,198 | June 1, 2017 | May 31, 2023 | LOPEZ-BERESTEIN, GABRIEL | reporter.nih.gov |
| Identifying Novel Radiation Sensitizers in Cervical Cancer | NIH | National Cancer Institute | 2023 to 2024 | $499,316 | December 7, 2022 | November 30, 2025 | COLBERT, LAUREN ELIZABETH | reporter.nih.gov |
| Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $499,256 | July 25, 2025 | March 31, 2027 | NASER, MOHAMED | reporter.nih.gov |
| Defining a globally accessible and pragmatic predictive signature (GAPPS) for locally advanced cervical cancer | NIH | National Cancer Institute | 2025 | $498,565 | September 8, 2025 | July 31, 2029 | KLOPP, ANN | reporter.nih.gov |
| QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCER | NIH | National Cancer Institute | 2021 to 2022 | $498,000 | July 1, 2020 | June 30, 2023 | WU, JIA | reporter.nih.gov |
| Bridging the gap: joint modeling of single-cell 1D and 3D genomics | NIH | National Human Genome Research Institute | 2024 to 2025 | $497,998 | September 2, 2024 | June 30, 2027 | ZHENG, YE | reporter.nih.gov |
| Genomic and Transcriptomic Analysis of Mammographic Density | NIH | National Cancer Institute | 2023 | $495,945 | December 11, 2019 | November 30, 2025 | SIEH, WEIVA | reporter.nih.gov |
| The role of ARF6 in the progression of diabetic kidney disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $495,720 | August 1, 2019 | May 31, 2025 | LIN, JAMIE | reporter.nih.gov |
| Redirected T Cell Therapy to Cure Invasive Fungal Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $491,996 | December 5, 2016 | November 30, 2022 | KONTOYIANNIS, DIMITRIOS P | reporter.nih.gov |
| Preclinical characterization of EMT/CSC-specific small molecule inhibitors for TNBCs | NIH | National Cancer Institute | 2021 | $483,655 | April 1, 2017 | December 1, 2022 | MANI, SENDURAI AYYAVOO | reporter.nih.gov |
| Pilot Study to Evaluate a Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers | NIH | National Institute on Drug Abuse | 2021 to 2022 | $483,057 | September 30, 2020 | August 31, 2024 | BLALOCK, JANICE ANITA | reporter.nih.gov |
| Regulation and function of nonlymphoid organ CD103+ dendritic cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $481,069 | August 24, 2021 | July 31, 2023 | WATOWICH, STEPHANIE S | reporter.nih.gov |
| Provider and Patient-generated Remote Oro-Dental Health Electronic Data Capture for Algorithmic Longitudinal Evaluation and Risk-Assessment (PROHEALER) | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2024 | $478,617 | September 1, 2022 | August 31, 2025 | MORENO, AMY CATHERINE | reporter.nih.gov |
| Obstetrical and Oncological Outcomes Among Reproductive Age Women with Gynecological and Breast Cancer | NIH | National Cancer Institute | 2021 to 2022 | $478,385 | September 18, 2018 | August 31, 2024 | RAUH-HAIN, JOSE ALEJANDRO | reporter.nih.gov |
| Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen | NIH | National Cancer Institute | 2021 to 2022 | $470,748 | June 17, 2019 | June 30, 2022 | KONOPLEVA, MARINA Y | reporter.nih.gov |
| Role of β-lactamase encoding gene amplification in the development of non-carbapenemase producing, carbapenem-resistant Enterobacteriaceae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $469,652 | March 17, 2021 | February 29, 2024 | SHELBURNE, SAMUEL A | reporter.nih.gov |
| Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | NIH | National Cancer Institute | 2025 | $465,168 | August 1, 2025 | May 31, 2027 | SMITH, JESSE JOSHUA | reporter.nih.gov |
| Fasting Protects Small Intestinal Stem Cells from Lethal DNA Damage: Mechanistic Insight and Preclinical Translation | NIH | National Cancer Institute | 2021 | $463,830 | March 14, 2017 | February 28, 2022 | PIWNICA-WORMS, HELEN M | reporter.nih.gov |
| Bio-engineered Cell Therapy to Treat Candidiasis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $461,625 | August 26, 2024 | July 31, 2027 | KUMAR, PAPPANAICKEN RANGASAMY | reporter.nih.gov |
| Investigating the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $460,940 | June 1, 2025 | May 31, 2027 | HUSE, JASON | reporter.nih.gov |
| Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $455,472 | August 18, 2021 | July 31, 2026 | HASSAN, NOHA ABDELWAHAB HASSAN ALI | reporter.nih.gov |
| Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $455,465 | September 1, 2023 | January 6, 2024 | BHAT, KRISHNA PL | reporter.nih.gov |
| Development of Risk and Early Detection Biomarker for Small Cell Lung Cancer | NIH | National Cancer Institute | 2021 | $455,339 | September 6, 2017 | August 31, 2022 | HANASH, SAMIR M | reporter.nih.gov |
| Defining novel mechanisms of clonal emergence in Group A Streptococcus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $452,750 | March 8, 2021 | February 29, 2024 | SHELBURNE, SAMUEL A | reporter.nih.gov |
| Diversity Supplement: Radiation-specific Automated Dental Dose Distributions via Machine-learning based Mapping for Accurate Predictions of (Peri)odontal Problems (RADMAP) | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2022 | $451,774 | September 1, 2022 | August 31, 2023 | MORENO, AMY CATHERINE | reporter.nih.gov |
| Computational and experimental approaches for decoding the function and regulation of unconventional RNA translation | NIH | National Institute of General Medical Sciences | 2025 | $449,625 | January 1, 2025 | November 30, 2029 | CHEN, YIWEN | reporter.nih.gov |
| Statistical methods to delineate the spatial and temporal pattern of cell-cell interactions in Spatial Transcriptomics data | NIH | National Institute of General Medical Sciences | 2025 | $449,625 | September 15, 2025 | July 31, 2030 | LI, ZIYI | reporter.nih.gov |
| Gut Microbiome, Antibiotic Use & Colon Cancer Recurrence | NIH | National Cancer Institute | 2021 | $446,142 | September 25, 2017 | August 31, 2025 | FEDIRKO, VERONIKA | reporter.nih.gov |
| Genetic determinants of early brain development in an animal model of autism spectrum disorder (ASD) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $445,500 | April 1, 2021 | March 31, 2024 | HOPKINS, WILLIAM D | reporter.nih.gov |
| Impact of regulatory cross-talk on the pathophysiology of emergent acapsular group A streptococcus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $445,500 | July 12, 2021 | June 30, 2025 | SHELBURNE, SAMUEL A | reporter.nih.gov |
| Development of fluorinated dyes for deeper tissue photoacoustic imaging with phase changing nanodroplets | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $445,500 | July 1, 2021 | April 30, 2024 | SOKOLOV, KONSTANTIN V | reporter.nih.gov |
| Mitokines as new targets for fatigue induced by mitochondrial stress | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $445,500 | September 15, 2022 | August 31, 2024 | DANTZER, ROBERT | reporter.nih.gov |
| Spatio-temporal regulation of ERK signaling by phosphatases in the female germline | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $445,500 | March 6, 2023 | February 28, 2025 | ARUR, SWATHI | reporter.nih.gov |
| Elucidating the Role of the Gut and Tumor Microbiome in Malignant Glioma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $445,500 | April 1, 2023 | March 31, 2026 | FERGUSON, SHERISE DESIREE | reporter.nih.gov |
| GS-441524 is Pharmacodynamically Equivalent to Remdesivir and Pharmacokinetically Superior Drug for the Treatment of COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $442,002 | January 1, 2021 | December 31, 2023 | LI, CHUN | reporter.nih.gov |
| Delineation of mechanisms underlying response regulator activation in group A Streptococcus | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $439,425 | February 1, 2024 | December 31, 2025 | SHELBURNE, SAMUEL A | reporter.nih.gov |
| Novel regulations of DNA damage repair | NIH | National Cancer Institute | 2021 | $436,368 | March 16, 2017 | February 28, 2024 | CHEN, JUNJIE | reporter.nih.gov |
| Resource for Nonhuman Primate Immune Reagents | NIH | Office of the Director, National Institutes of Health | 2025 | $434,233 | April 1, 2002 | March 31, 2027 | VILLINGER, FRANCOIS J | reporter.nih.gov |
| Inhibition of brain metastasis by blocking MAPK12 driver kinase functions | NIH | National Cancer Institute | 2021 | $432,573 | June 1, 2017 | November 30, 2022 | YU, DIHUA | reporter.nih.gov |
| IL13Ra2-targeted radioimmunotherapy for glioblastoma | NIH | National Cancer Institute | 2025 | $432,134 | June 5, 2025 | May 31, 2027 | KREBS, SIMONE | reporter.nih.gov |
| Parenting Intervention for Caregivers who Parent a Young Child while Caring for a Spouse with an Incurable Cancer. | NIH | National Cancer Institute | 2021 | $429,771 | September 23, 2021 | August 31, 2024 | MILBURY, KATHRIN | reporter.nih.gov |
| Modeling tumor heterogeneity and treatment resistance in small cell lung cancer | NIH | National Cancer Institute | 2021 to 2024 | $426,837 | September 4, 2020 | August 31, 2025 | STEWART, CATHERINE ALLISON | reporter.nih.gov |
| Integrating in vivo and in silico models of prostate cancer-bone interactions to overcome anti-tumor therapy resistance | NIH | National Cancer Institute | 2022 to 2023 | $425,970 | August 1, 2022 | July 31, 2024 | DONDOSSOLA, ELEONORA | reporter.nih.gov |
| Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer | NIH | National Cancer Institute | 2021 | $425,403 | September 1, 2017 | August 31, 2023 | YANG, LIUQING | reporter.nih.gov |
| Detection and elimination of drug tolerant persister cells in small cell lung cancer | NIH | National Cancer Institute | 2025 | $424,836 | April 11, 2025 | March 31, 2030 | GAY, CARL MICHAEL | reporter.nih.gov |
| Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients | NIH | National Cancer Institute | 2022 to 2023 | $424,713 | September 1, 2022 | August 31, 2025 | MILBURY, KATHRIN | reporter.nih.gov |
| Targeting a Novel Secreted Immune Checkpoint to Enhance Liver Cancer Immunotherapy | NIH | National Cancer Institute | 2025 | $421,685 | August 1, 2025 | July 31, 2027 | DENG, YALAN | reporter.nih.gov |
| Pan-cancer Analysis of Convergent Immunoglobulins from Tumor-infiltrating B Cells | NIH | National Cancer Institute | 2025 | $421,685 | August 1, 2025 | July 31, 2027 | LIU, BIN | reporter.nih.gov |
| Molecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinoma | NIH | National Cancer Institute | 2022 | $421,346 | September 1, 2022 | August 31, 2023 | SONG, SHUMEI | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 345 | $218,589,105 | 0 | $0 |
| 2024 | 355 | $191,991,851 | 0 | $0 |
| 2023 | 352 | $193,976,497 | 0 | $0 |
| 2022 | 352 | $179,819,126 | 1 | $242,477 |
| 2021 | 346 | $172,498,960 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Cancer
- Genetics
- Rare Diseases
- Clinical Research
- Biotechnology
- Immunotherapy
- Translational Research
- Orphan Drug
- Human Genome
- Prevention
- Digestive Diseases
- Cancer Genomics
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.